Mauna Kea Technologies news

The new Cellvizio^®platform includes significant improvements and will enable major innovations 

Mauna Kea Technologies announced today that it has obtained 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking of the next-generation Cellvizio^® endomicroscopy platform, built with the company’s new proprietary system

The Cellvizio^®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries 

Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio^® 100 series and all associated Confocal Miniprobes™ for the additional indication of visualization of blood flow when

Clinical trial published in peer-reviewed journal demonstrates diagnostic yield from Cellvizio^®significantly exceeds standard of care (84.1% vs 34.1%); use of Cellvizio drives overall change in clinical management - including need for continued surveillance or surgery - in 42.3% of cases

Mauna Kea Technologies today announced a publication that demonstrates how Cellvizio positively impacts the diagnostic yield and the clinical management of pancreatic cystic lesion

MEDPHOT consortium aims to develop light-based molecular imaging solution for pulmonary diseases 

Mauna Kea Technologies today announced it is part of a molecular imaging consortium that was awarded €5.4 million by the Perspective Program of the Netherlands Organization for Scientific Research (NWO).

Molecular imaging provides insight into molecular and cellular processes in the body, and has the potential to transform healthcare by offering earlier detection an